IN SELECT HEMATOLOGIC TUMOR TYPES

The following data compilation of 1181 patients from 23 peer reviewed published articles in select hematologic tumor types establish the positive predictive accuracy of cell death assays at 81.8% and negative predictive accuracies of 83.3%. This breakdown reveals compelling evidence that assay directed therapies could improve response rates, time to progression and survival.

Positive Predictive Accuracy 81.8%
False Positive 12.4%
When assay predicted sensitivity, there was response.

Negative Predictive Accuracy 83.3%
False Negative 5.2%
When assay predicted resistance, there was no response.

REFERENCE LITERATURE

• 1. Leone LA, Meitner PA, Myers TJ et al. Predictive value of fluorescent cytoprint assay (FCA): A retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy. Cancer Invest 1991; 9:491-503.



• 2. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet 1991; 337: 711-716.



• 3. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia. Cancer 1990; 65: 1263-1272.



• 4. Hongo T, Fujii Y, Yajima S. In vitro chemosensitivity of childhood leukemic cells and the clinical value of assay directed chemotherapy. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug resistance in leukemia and lymphoma. Langhorne, PA: Harwood Academic Publishers, 1993:319.



• 5. Kaspers GJL, Pieters R, Van Zantwijk CH, De Waal FC, Van Wering ER, Veerman AJP. Is resistance to prednisolone in vitro related to the response to predniso(lo)ne in vivo at initial diagnosis in childhood acute lymphoblastic leukemia? – a preliminary analysis. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 321-328.



• 6. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992; 50: 177-185.



• 7. Lathan B, von Tettau M, Verpoort K, Diehl V. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis. Haematol Blood Transfus 1990; 33: 295-298.



• 8. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM. Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep 1986; 70: 1283-1295.



• 9. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 1983; 43: 749-757.



• 10. Kirkpatric DL, Duke M, Goh TS. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium, dye (MTT) assay. Leuk Res 1990; 14: 459-466.



• 11. Langker ST, Norgaard JM. Use of the MTT-assay for evaluation of chemosensitivity in adult acute myeloid leukemia. In: Kaspers GJ, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 279-291.



• 12. Staib P, Lathan B, Schinkothe T, et al. Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index C1. Adv Exper Med Biol 1999; 457: 437-444.



• 13. Santini V, Bernabei PA, Dal Pozzo O, Santini S, Rossi Ferrini P. Acute myeloid leukemia (AML) sensitivity to antiblastics is predictable by the INT assay. In: Kaspers GJ, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 365-368.



• 14. Sargent JM, Taylor CG. Appraisal of the MTT assay as a rapid test of chjemosensitivity in acute myeloid leukaemia. Br J Cancer 1989; 60: 206-210.



• 15. Stute N, Kohler T, Lehmann L.. Drug resistance testing in acute myeloid leukemia. Adv Exper Med Biol 1999; 457: 445-452.



• 16. Larsson R, Jonsson B, Kristensen J, et al. Drug sensitivity testing of tumor cells from patients with acute leukemia and non-Hodgkin’s lymphoma using a fluorometric microculture cytotoxicity assay. In: Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 399-407.



• 17. Beksac M, Kansu E, Kars A, Ibrahimoglu Z, Firat D. A rapid drug sensitivity assay for neoplasmatic cells. Med Oncol Tumor Pharmacother 1988; 5: 253-257.



• 18. Santini V, Bernabei PA, Silvestro L, et al. In vitro chemosensitivity testing of leukemic cells: prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. Hematol Oncol 1989; 7: 287-93.



• 19. Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations. Eur J Haematol 1989; 43: 374-384.



• 20. Bosanquet AG, Copplestone JA, Johnson SA, et al. Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay. Br J Haematol 1999; 106: 474-476.



• 21. Silber R, Degar B, Costin D, et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to Chlorambucil, fludarabine, and camptothecin analogs. Blood 1994; 84: 3440-3446.



• 22. Bosanquet AG. The DiSC assay – 10 years and 2000 tests further on. In: Kasper GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur: Harwood Academic Publishers, 1993: 373-383.



• 23. Sevin B-U, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynec Oncol 1988; 31: 191-204.